Complete response to sunitinib in a patient with relapsed irresectable renal cell carcinoma

Anticancer Drugs. 2011 Sep;22(8):817-21. doi: 10.1097/CAD.0b013e3283437ff9.

Abstract

We report a case with a complete pathology-proven remission after sunitinib treatment of a relapsed irresectable clear cell renal carcinoma. A significant objective response was observed with tumor size reduction during treatment. After surgery, on pathologic examination it was concluded that the patient exhibited a complete response; activity and the feasibility and safety of subsequent surgical resection were assessed. Otherwise after discontinuing sunitinib, the patient had a relapse on the same location; sunitinib has been resumed and was again found to be effective.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Carcinoma, Renal Cell / drug therapy*
  • Carcinoma, Renal Cell / pathology
  • Carcinoma, Renal Cell / surgery
  • Combined Modality Therapy
  • Humans
  • Indoles / therapeutic use*
  • Kidney Neoplasms / drug therapy*
  • Kidney Neoplasms / pathology
  • Kidney Neoplasms / surgery
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local
  • Pyrroles / therapeutic use*
  • Remission Induction / methods
  • Sunitinib
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Indoles
  • Pyrroles
  • Sunitinib